MYLK and hepatocellular carcinoma: For example, lncRNA MYLK-AS1 facilitates HCC progression and angiogenesis by promoting the invasion and metastatic abilities of HCC cells in vivo through targeting the miR-424-5p/E2F7 axis and activating the VEGFR-2 signalling pathway [55].